Want to see GPCR full AI Analyst Report?
GPCR Stock Chart & Stats
$50.75
-$0.32(-1.18%)
At close: 4:00 PM EST
$50.75
-$0.32(-1.18%)
Day’s Range― - ―
52-Week Range$15.80 - $94.90
Previous CloseN/A
Volume219.80K
Average Volume (3M)839.70K
Market Cap
$3.45B
Enterprise Value$2.28B
Total Cash (Recent Filing)$1.46B
Total Debt (Recent Filing)$5.79M
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Aug 06, 2026EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.64
Shares Outstanding71,074,520
10 Day Avg. Volume648,387
30 Day Avg. Volume839,696
Financial Highlights & Ratios
PEG Ratio-11.30
Price to Book (P/B)2.72
Price to Sales (P/S)0.00
P/FCF Ratio-18.23
Enterprise Value/Market Cap0.66
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.87K
Enterprise Value/Ebitda-13.59
Forecast
1Y Price Target
$110.17Price Target Upside117.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.43
Revenue Forecast (FY)$38.46M
Bulls Say, Bears Say
Bulls Say
Low Leverage And Sizable Equity BaseA large equity base and negligible debt provide durable financial flexibility to fund multi-year R&D programs. This reduces refinancing risk during clinical development, supports capital-intensive Phase 3 plans, and lowers bankruptcy/default probability while the company pursues commercialization.
Strong Phase 2 Obesity Efficacy And FDA FeedbackRobust Phase 2 efficacy and constructive FDA end-of-Phase 2 feedback materially de-risk the lead program's development path. Durable clinical differentiation for an oral obesity therapy strengthens the company's long-term market positioning versus injectables and supports a clear path to Phase 3.
Substantial Cash Runway And Expanded ATM CapacityA reported $1.5B cash balance plus an enlarged ATM gives sustained funding visibility into pivotal development stages. This financing optionality supports planned Phase 3 investment and optionality to unlock value without immediate reliance on dilutive bulk financings, ensuring program continuity.
Bears Say
Pre-revenue With Widening Operating LossesAbsence of product revenue and materially larger operating losses create enduring profitability risk until late-stage success or commercialization. Persistent negative earnings increase reliance on external financing and mean value is highly contingent on clinical outcomes and regulatory approvals.
Persistent Heavy Cash Burn And Deteriorating FCFConsistent negative operating cash flow and worsening free cash flow growth indicate accelerating cash consumption to support trials. Over the medium term this raises financing frequency and execution risk if clinical timelines slip or costs rise, pressuring strategic optionality.
Dilution Risk From Open ATM And Funding NeedsWhile the expanded ATM improves financing optionality, an uncapped issuance capacity creates structural dilution risk as the company funds costly Phase 3 programs. Repeated capital raises could erode per-share economics and influence investor returns absent clinical or commercial milestones.
Structure Therapeutics, Inc. Sponsored ADR News
GPCR FAQ
What was Structure Therapeutics, Inc. Sponsored ADR’s price range in the past 12 months?
Structure Therapeutics, Inc. Sponsored ADR lowest stock price was $15.80 and its highest was $94.90 in the past 12 months.
What is Structure Therapeutics, Inc. Sponsored ADR’s market cap?
Structure Therapeutics, Inc. Sponsored ADR’s market cap is $3.45B.
When is Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date?
Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date is Aug 06, 2026 which is in 15 days.
How were Structure Therapeutics, Inc. Sponsored ADR’s earnings last quarter?
Structure Therapeutics, Inc. Sponsored ADR released its earnings results on May 07, 2026. The company reported -$0.35 earnings per share for the quarter, beating the consensus estimate of -$0.351 by $0.001.
Is Structure Therapeutics, Inc. Sponsored ADR overvalued?
According to Wall Street analysts Structure Therapeutics, Inc. Sponsored ADR’s price is currently Undervalued.
Does Structure Therapeutics, Inc. Sponsored ADR pay dividends?
Structure Therapeutics, Inc. Sponsored ADR does not currently pay dividends.
What is Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate?
Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate is -0.38.
How many shares outstanding does Structure Therapeutics, Inc. Sponsored ADR have?
Structure Therapeutics, Inc. Sponsored ADR has 71,074,520 shares outstanding.
What happened to Structure Therapeutics, Inc. Sponsored ADR’s price movement after its last earnings report?
Structure Therapeutics, Inc. Sponsored ADR reported an EPS of -$0.35 in its last earnings report, beating expectations of -$0.351. Following the earnings report the stock price went down -0.128%.
Which hedge fund is a major shareholder of Structure Therapeutics, Inc. Sponsored ADR?
Currently, no hedge funds are holding shares in GPCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Structure Therapeutics, Inc. Sponsored ADR Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$110.17 (117.08% Upside)
$110.17 (117.08% Upside)
Blogger Sentiment
Bullish
GPCR Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 475.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.8%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
172.20%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
74.04%
Trailing 12-Months
Company Description
Structure Therapeutics, Inc. Sponsored ADR
Structure Therapeutics Inc., an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various chronic diseases that lack adequate treatment options. The company's primary investigational drug, GSBR-1290, is an orally administered, biased small molecule agonist designed to target the glucagon-like-peptide-1 receptor (GLP-1R). This G-protein-coupled receptor (GPCR) is a recognized and validated therapeutic target for managing both type-2 diabetes mellitus and obesity. Furthermore, Structure Therapeutics is developing other oral small molecule treatments that act on different GPCRs, addressing pulmonary and cardiovascular conditions. For example, ANPA-0073 is a biased agonist aimed at the apelin receptor, a GPCR linked to diseases like idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension. Another compound in their pipeline is LTSE-2578, an oral small molecule that acts as a lysophosphatidic acid 1 receptor antagonist, also being explored for the treatment of IPF. Established in 2016, the company was formerly known as ShouTi Inc. and is headquartered in South San Francisco, California.
GPCR Stock 12 Month Forecast
Average Price Target
$110.17
▲(117.08% Upside)
Technical Analysis
Ownership Overview
10.08% Insiders
26.29% Mutual Funds
0.22% Other Institutional Investors
62.12% Public Companies and Individual Investors